Andrx Extended Release Lovastatin Tradename Moves From Avicor To Altocor
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Andrx has changed the proposed tradename for its extended-release lovastatin product from Avicor to Altocor. The firm submitted an NDA for the cholesterol-lowering agent March 30, suggesting an FDA review goal of January 2002. Andrx says it expects to hear from FDA by second quarter 2002.